Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. to keep PSE meds BTC

This article was originally published in The Tan Sheet

Executive Summary

Restrictions on sales of drugs containing ephedrine and pseudoephedrine in the U.K. have proven effective in decreasing illicit methylamphetamine production, so the Medicines and Healthcare products Regulatory Agency will not shift the products to prescription only status. In August 2007, an agency advisory panel recommended ephedrine and PSE products be sold in packages no larger than 720 mg and its Commission on Human Medicines recommended limiting sales of the drugs to pharmacy only and to one package per person (1"The Tan Sheet" Jan. 14, 2008). MHRA said July 29 in wake of the changes, meth abuse has been contained and pharmacies have seen a 25 percent drop in PSE purchases. An executive said the agency will continue to monitor sales of the meth precursors

You may also be interested in...

Pharmacy PSE in U.K. works

A U.K. advisory panel determines behind-the-counter sales of nonprescription products containing epehedrine or pseudoephedrine effectively mitigate misuse of the drugs. The Medicines and Healthcare products Regulatory Agency's Commission on Human Medicines concluded in July that regulatory measures are "successful" and recommends maintenance of existing pharmacist monitoring and education programs. The report follows MHRA's July 2009 decision to not make precursors of methamphetamine prescription-only (1"The Tan Sheet" Aug. 3, 2009, In Brief)

U.K. Industry Asks For More Time To Prepare For Limits On OTC PSE Sales

U.K. drug firms say the country's regulatory agency is not allowing enough time to comply with an order banning nonprescription access to product packages with more than 720 mg of pseudoephedrine beginning April 1

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts